Summary of patient best responses as assessed by an IEAC
| Population . | N . | ORR, n (%) . | CR, n (%) . | CRu, n (%) . | PR, n (%) . | SD, n (%) . | PD, n (%) . |
|---|---|---|---|---|---|---|---|
| All patients | 25 | 12 (48.0) | 5 (20.0) | 0 | 7 (28.0) | 10 (40.0) | 3 (12.0) |
| ATL subtype | |||||||
| Acute | 16 | 10 (62.5) | 5 (31.3) | 0 | 5 (31.3) | 4 (25.0) | 2 (12.5) |
| Lymphoma | 6 | 1 (16.7) | 0 | 0 | 1 (16.7) | 5 (83.3) | 0 |
| Unfavorable chronic | 3 | 1 (33.3) | 0 | 0 | 1 (33.3) | 1 (33.3) | 1 (33.3) |
| Disease site | |||||||
| Nodal or extranodal lesions | 20 | 10 (50.0) | 6 (30.0) | 2 (10.0) | 2 (10.0) | 7 (35.0) | 3 (15.0) |
| Skin lesions∗ | 7 | 3 (42.9) | 1 (14.3) | Not evaluable | 2 (28.6) | 3 (42.9) | 0 |
| Peripheral blood | 9 | 8 (88.9) | 2 (22.2) | Not evaluable | 6 (66.7) | 1 (11.1) | 0 |
| Disease status | |||||||
| Relapsed | 8 | 3 (37.5) | 1 (12.5) | 0 | 2 (25.0) | 4 (50.0) | 1 (12.5) |
| Recurrent | 6 | 4 (66.7) | 1 (16.7) | 0 | 3 (50.0) | 2 (33.3) | 0 |
| Refractory | 11 | 5 (45.5) | 3 (27.3) | 0 | 2 (18.2) | 4 (36.4) | 2 (18.2) |
| Prior mogamulizumab treatment | |||||||
| Yes | 24 | 11 (45.8) | 4 (16.7) | 0 | 7 (29.2) | 10 (41.7) | 3 (12.5) |
| No | 1 | 1 (100.0) | 1 (100.0) | 0 | 0 | 0 | 0 |
| Prior lenalidomide treatment | |||||||
| Yes | 8 | 4 (50.0) | 0 | 0 | 4 (50.0) | 3 (37.5) | 1 (12.5) |
| No | 17 | 8 (47.1) | 5 (29.4) | 0 | 3 (17.6) | 7 (41.2) | 2 (11.8) |
| Population . | N . | ORR, n (%) . | CR, n (%) . | CRu, n (%) . | PR, n (%) . | SD, n (%) . | PD, n (%) . |
|---|---|---|---|---|---|---|---|
| All patients | 25 | 12 (48.0) | 5 (20.0) | 0 | 7 (28.0) | 10 (40.0) | 3 (12.0) |
| ATL subtype | |||||||
| Acute | 16 | 10 (62.5) | 5 (31.3) | 0 | 5 (31.3) | 4 (25.0) | 2 (12.5) |
| Lymphoma | 6 | 1 (16.7) | 0 | 0 | 1 (16.7) | 5 (83.3) | 0 |
| Unfavorable chronic | 3 | 1 (33.3) | 0 | 0 | 1 (33.3) | 1 (33.3) | 1 (33.3) |
| Disease site | |||||||
| Nodal or extranodal lesions | 20 | 10 (50.0) | 6 (30.0) | 2 (10.0) | 2 (10.0) | 7 (35.0) | 3 (15.0) |
| Skin lesions∗ | 7 | 3 (42.9) | 1 (14.3) | Not evaluable | 2 (28.6) | 3 (42.9) | 0 |
| Peripheral blood | 9 | 8 (88.9) | 2 (22.2) | Not evaluable | 6 (66.7) | 1 (11.1) | 0 |
| Disease status | |||||||
| Relapsed | 8 | 3 (37.5) | 1 (12.5) | 0 | 2 (25.0) | 4 (50.0) | 1 (12.5) |
| Recurrent | 6 | 4 (66.7) | 1 (16.7) | 0 | 3 (50.0) | 2 (33.3) | 0 |
| Refractory | 11 | 5 (45.5) | 3 (27.3) | 0 | 2 (18.2) | 4 (36.4) | 2 (18.2) |
| Prior mogamulizumab treatment | |||||||
| Yes | 24 | 11 (45.8) | 4 (16.7) | 0 | 7 (29.2) | 10 (41.7) | 3 (12.5) |
| No | 1 | 1 (100.0) | 1 (100.0) | 0 | 0 | 0 | 0 |
| Prior lenalidomide treatment | |||||||
| Yes | 8 | 4 (50.0) | 0 | 0 | 4 (50.0) | 3 (37.5) | 1 (12.5) |
| No | 17 | 8 (47.1) | 5 (29.4) | 0 | 3 (17.6) | 7 (41.2) | 2 (11.8) |
RD: received ≥1 prior chemotherapy, achieved CR or CRu, and subsequently experienced disease progression. Recurrent disease: received ≥1 prior chemotherapy, achieved PR, and subsequently experienced disease progression. Refractory: received ≥1 prior chemotherapy and either achieved SD requiring a treatment switch or subsequently experienced PD.
One patient was not evaluated for skin lesions after baseline assessment.